The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver.
about
Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patientsInsights into CYP2B6-mediated drug-drug interactionsCYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine.Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene.The Impact of CYP2D6 Genotyping on Tamoxifen TreatmentConcomitant use of tamoxifen and endoxifen in postmenopausal early breast cancer: prediction of plasma levels by physiologically-based pharmacokinetic modeling.Genotype-guided tamoxifen therapy: time to pause for reflection?High-throughput and combinatorial gene expression on a chip for metabolism-induced toxicology screening.CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors.CYP2B6: new insights into a historically overlooked cytochrome P450 isozymeUridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis.Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer.Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversyClinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes.Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variantsOxidative metabolism of tamoxifen to Z-4-hydroxy-tamoxifen by cytochrome P450 isoforms: an appraisal of in vitro studies.Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity.Development of an in vitro system with human liver microsomes for phenotyping of CYP2C9 genetic polymorphisms with a mechanism-based inactivatorEffects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen.Physiologically Based Pharmacokinetic Modeling of Tamoxifen and its Metabolites in Women of Different CYP2D6 Phenotypes Provides New Insight into the Tamoxifen Mass Balance.Endocrine resistance in breast cancer--An overview and update.Bioactivation of the cancer chemopreventive agent tamoxifen to quinone methides by cytochrome P4502B6 and identification of the modified residue on the apoproteinInsights into the role of heritable genetic variation in the pharmacokinetics and pharmacodynamics of anticancer drugs.Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram.New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer.Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen.Do single nucleotide polymorphisms in xenobiotic metabolizing genes determine breast cancer susceptibility and treatment outcomes?Pharmacogenetics of solid tumors: directed therapy in breast, lung, and colorectal cancer: a paper from the 2008 william beaumont hospital symposium on molecular pathology.No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medicationsCytochrome P450 2C9-CYP2C9.Impact of CYP2D6 polymorphism on tamoxifen therapy: where are we?Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer.Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies.CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen.CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset.CCAAT/enhancer-binding protein alpha (C/EBPalpha) and hepatocyte nuclear factor 4alpha (HNF4alpha) synergistically cooperate with constitutive androstane receptor to transactivate the human cytochrome P450 2B6 (CYP2B6) gene: application to the develDrug interaction potential of toremifene and N-desmethyltoremifene with multiple cytochrome P450 isoforms.Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes.
P2860
Q24810279-C772D2F4-EF06-4FB3-AC2A-B10C88F1007BQ28078857-F04D5A41-A39A-4BA3-B682-10790553ACA2Q30400967-D2EF92FE-23CE-47EA-86B1-57CF90D4D886Q30440152-9319E1A9-EA43-4033-9A0E-15233CB6D9ACQ33664433-A200C335-5ABF-42C7-BBDF-2C25C398D8D4Q33756964-1DFB76E1-9A93-4D90-B04C-5C5063864E76Q33955759-EB39F787-18B2-4F85-ADA0-F2854BBA7DADQ34044936-F433CC18-443F-415E-B51B-240201EE42C4Q34677193-A14BE5B7-122C-4EB3-94A4-36A7B7123671Q34774040-BCF75C35-A15A-4F04-BAE9-7179B1930777Q34824471-515181BC-58B8-4AC8-895D-926754584018Q35008045-D44DFA3C-0A6D-41DD-A4CF-D4E634A02D59Q35009604-63FDF914-BB0F-4EB0-A53B-FC4302ECF892Q35020403-B48B8287-81FE-4E40-84E8-7252C77A868DQ35056229-21507B5D-0657-451F-A8AF-03D3D4955046Q35058455-9A948707-AD0B-45AE-A74F-0FE9EABA0F03Q35605724-2A37F62C-E118-46E4-8CAA-AE47ED7F7109Q35608859-A2E1CC81-5476-4E5C-899E-72FF6DFEE1F8Q35825872-19AF9563-9DDC-40E5-81B4-D00FA9B09414Q35846894-88865D56-3CD1-4220-B017-1A865097F202Q35884159-90B7E052-D410-4A8D-9213-6DEBC57A41B8Q35975826-8AFF722B-9607-42C1-94B6-4E39A156C8B2Q36386322-CC057A43-680B-4197-9528-1D85F1157D63Q36406301-95C941AE-4ED0-461A-9B6E-F226549E7F98Q36847276-1F73D15A-36EB-49EB-BE54-94B30CB8156EQ36858268-56C0A529-BD60-4C15-8278-B303292C1EB8Q36927087-5D207C48-B1FD-4C78-9F20-F95FA233721AQ37221922-C92232FA-9EA0-4792-BACC-DA3D3127B83CQ37271799-F6FDBFBC-3930-4BD5-A06B-920B88409AB8Q37312970-91FDB4F8-1D83-44C9-8BA0-FAE2A1BEF2C1Q37343277-10192633-A330-46C3-8B06-695F711E512EQ37691210-0CE3331C-9D9C-4B3C-B8F9-20E1A8E3A865Q38017920-F7963408-8A68-4B32-BD70-D3D75345A1EDQ38103593-158BF044-E4FE-467D-A430-63025F9D488AQ38105253-5864BB58-ADAA-456B-BEE2-BB4C2879F115Q38442184-1C972E97-01CB-4CD5-B2E2-0182FC434CEAQ38629670-79428F7A-A9A4-473C-8CC3-690CADD979B9Q42140049-C1B116F5-6362-4336-99C0-37995D1891C1Q43552073-94ADCEC9-1F30-46FA-8379-26BE928F7C74Q44642230-077B12C8-4E72-4AA5-9B74-7A3F707EFCD3
P2860
The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
The influence of CYP2B6, CYP2C ...... roxy-tamoxifen in human liver.
@ast
The influence of CYP2B6, CYP2C ...... roxy-tamoxifen in human liver.
@en
type
label
The influence of CYP2B6, CYP2C ...... roxy-tamoxifen in human liver.
@ast
The influence of CYP2B6, CYP2C ...... roxy-tamoxifen in human liver.
@en
prefLabel
The influence of CYP2B6, CYP2C ...... roxy-tamoxifen in human liver.
@ast
The influence of CYP2B6, CYP2C ...... roxy-tamoxifen in human liver.
@en
P2093
P2860
P1476
The influence of CYP2B6, CYP2C ...... roxy-tamoxifen in human liver.
@en
P2093
Andreas Nüssler
Janet K Coller
Karin Endrizzi
Kathrin Klein
Michel Eichelbaum
Niels Krebsfaenger
Renzo Wolbold
Thomas E Mürdter
Thomas Lang
P2860
P304
P356
10.1046/J.1365-2125.2002.01614.X
P407
P577
2002-08-01T00:00:00Z